Matthew Hillegass, MD
Family Medicine · New Paris, PANPI 1346691813
Payments from drug & device makers
Across 951 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Pfizer$1K
- AstraZeneca$1K
- Lilly USA, LLC$934
- GSK$465
- plus $7K from 54 others
What the payments were for
- Food & beverage$14,37599%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$259
- AIRSUPRA$147
- BREZTRI$147
- BREZTRI AEROSPHERE$112
- FASENRA$112
- SYMBICORT$112
- WATCHMAN FLX$108
How this compares
$14,475 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 384 | $316,703 |
| JardianceEmpagliflozin | 282 | $258,317 |
| OzempicSemaglutide | 101 | $129,060 |
| XareltoRivaroxaban | 141 | $122,513 |
| MounjaroTirzepatide | 92 | $112,094 |
| TrulicityDulaglutide | 95 | $103,940 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $98,486 |
| FarxigaDapagliflozin Propanediol | 91 | $97,669 |
| EntrestoSacubitril/Valsartan | 107 | $88,337 |
| TradjentaLinagliptin | 63 | $57,726 |
| Repatha SureclickEvolocumab | 60 | $53,460 |
| LinzessLinaclotide | 54 | $44,512 |
| JanuviaSitagliptin Phosphate | 25 | $37,306 |
| Nurtec OdtRimegepant Sulfate | 19 | $28,638 |
| RexultiBrexpiprazole | 12 | $26,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $1,350 | $345,340403 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Synjardy Xr | $290 | $333,117374 claims |
| Lilly USA, LLCMounjaro, Trulicity | $934 | $216,034187 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,366 | $162,158126 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $465 | $140,558183 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,065 | $128,347141 claims |
| Johnson & JohnsonXarelto | $95 | $122,513141 claims |
| NovartisEntresto | $436 | $88,337107 claims |
| AbbVieLinzess | $2,405 | $44,51254 claims |
| MerckJanuvia | $381 | $37,30625 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $413 | $26,10812 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $122 | $25,27518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in New Paris
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.